Mirum Pharmaceuticals Inc (MIRM) Stock Analysis
Verdict: BUY
Clinical success in PSC transforms Mirum from a niche pediatric player into a multi-billion dollar rare disease powerhouse with positive FCF.
Investment score: 72/100
Analysis as of
Is Mirum Pharmaceuticals Inc stock worth reviewing? The TradeMates thesis
The model identifies MIRM as a high-conviction growth play due to its rare liver disease drug success and improving fundamentals.
7-factor investment score
- Valuation: 55/100 (weight 20%)
- Financial Health: 85/100 (weight 15%)
- Technical Momentum: 80/100 (weight 15%)
- Earnings Quality: 65/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 90/100 (weight 10%)
- Risk-Adjusted Return: 75/100 (weight 15%)
Mirum Pharmaceuticals Inc opportunities and risks
What speaks for MIRM
- Volixibat Market Expansion
What speaks against MIRM
- Regulatory/Clinical Binary Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| MIRM | n/a | 10.2x | 382.2x | 80.8% | -4.5% | 1.0% |
| CELC | n/a | 0.0x | n/a | 0.0% | 0.0% | -2.2% |
| KYMR | n/a | 131.2x | n/a | 100.0% | -612.2% | -3.6% |
| PTGX | n/a | 357.8x | n/a | 97.9% | -648.3% | -1.8% |
| RYTM | n/a | 29.0x | n/a | 89.4% | -93.8% | -1.9% |
| APGE | n/a | 0.0x | n/a | 0.0% | 0.0% | -4.5% |
| Peer median | n/a | 29.0x | n/a | 89.4% | -93.8% | -2.2% |
Frequently asked questions about Mirum Pharmaceuticals Inc (MIRM)
Is MIRM stock a good investment?
The TradeMates model rates Mirum Pharmaceuticals Inc as BUY with an investment score of 72/100. The model identifies MIRM as a high-conviction growth play due to its rare liver disease drug success and improving fundamentals. This is algorithmic model output, not personal investment advice.
Is MIRM stock a buy?
The TradeMates model verdict for MIRM is BUY with an investment score of 72/100. Treat this as a model signal to review, not a personal buy recommendation.